Langdurige chemotherapie-geinduceerde neutropenie
Inhoudsopgave
- overview Euroflow
1 AML
Myeloïde leukemie | Myelo-Monocytaire leukemie | Myelo | Mono | APL | Erytroblastair | Megakaryoblastair |
---|---|---|---|---|---|---|
CD34 | CyMPO | CyMPO | CyMPO | CyMPO (sterk!) | CD36 | CD41/CD61 |
CD117 | CD34 | (HLA-DR) | HLA-DR | CD13 | H-antigeen | CD42 |
HLA-DR | CD117 | CD13 | CD13 | CD33 | CD235a (GpA) | |
(CyMPO) | HLA-DR | CD33 | CD33 | HLA-DR neg | CD14 neg | |
(CD34) | CD13 | CD15 | CD11b/c | CD15 vaak neg | CD41/61 neg | |
(CD7) | CD33 | CD14 | HLA-DR neg | |||
(CD13) | (CD11b/c) | CD36 | ||||
(CD33) | (CD15) |
2 T-ALL
Pro-T | Onrijp | Common | Rijp |
---|---|---|---|
CyTdT | CyTdT | CyTdT | CyTdT |
HLA-DR | CyCD3 | CD2 | CD2 |
CD7 | CD2 | CD7 | CD7 |
CyCD3 | CD7 | CyCD3 | CyCD3 |
(CD34) | CD5 | CD5 | TCR-CD3 |
(CD2) | CD1a | CD5 | |
(TCR-CD3) | (CD4 en/of CD8) | ||
(CD10) | |||
(CD4 en/of CD8) |
3 Voorloper B-celmaligniteit
Pro-B (null) | common | Pre-B |
---|---|---|
CyTdT | CyTdT | CyTdT |
HLA-DR | HLA-DR | HLA-DR |
CyCD79a | CyCD79a | CyCD79a |
CD19 | CD19 | CD19 |
CD22 | CD22 | CD22 |
CD34 | CD10 | CD10 |
(CD20) | CyIgµ (zwak) | |
(CD34) | (CD20) | |
(CD34) |
4 Rijpe B-celleukemie
B-CLL | B-PLL | HCL | HCLv | MCL | FCL | Burkitt | MALT | SLVL | LPL | MM/PCL | |
---|---|---|---|---|---|---|---|---|---|---|---|
SmIg | ++w | ++s | ++ | ++s | ++s | ++s | ++ | ++ | ++s | ++ | - |
CyIg | ± | ± | - | - | - | - | - | +p | +p | ++ps | ++s |
IgH-isotype | m, d (g, a) | m, d (g ,a ) | m, d ,g ,a | g | m, d | m, d, g | m, d | m, g, a | m, d, g | m (d) | g, a (d, e) |
CD19 | ++ | ++ | ++ | ++ | ++w | ++ | ++ | ++ | ++ | ++ | - |
CD20 | ++w | ++s | ++s | ++ | ++s | ++ | ++ | ++ | ++ | ++ | - |
CD22 | +w | ++s | ++s | ++ | + | ++ | ++ | ++ | ++s | ++ | - |
CD23 | ++ | + | - | ± | - | ± | - | - | ± | - | - |
CD24 | ++ | ++ | ± p | - | ++ | ++ | ++ | ++ | ++ | ++ | - |
CD5/CD6 | ++ | ± (30%) | - | - | ++ | ± | - | - | ± | ± | - |
CD10 | - | ± | ± | ± | ± | +w | ++s | - | ± | - | - |
CD11c | + | - | ++ | + | - | - | - | + | + | ± | - |
CD22 | ++s | ++w | + | + | + | ||||||
CD23 | +/- ? | ± | - | - | +w | ||||||
CD25 | +w | - | ++ | - | - | - | - | ± | ± | ± | - |
CD79b | ++w | + | + | + | + | ||||||
CD103 | - | - | ++ | + | - | - | - | - | ± | - | - |
CD138 | - | - | - | - | - | - | - | - | - | + | ++ |
CD200 | ++ | -/+w | ± (30%) | ||||||||
FMC7 | ± | ++s | ++ | ++ | + | ++ | ? | ++ | ++ | ++ | - |
CD5 | ++ | ± |
- - , <10% van de maligniteiten is positief
- ± , 10-25% van de maligniteiten is positief
- +, 25-75% van de maligniteiten is positief
- ++, >75% van de maligniteiten is positief
- w, zwakke expressie
- s, sterke expressie
- p, expressie op een deel van de leukemiecellen
5 Rijpe T-celeukemie
- zie ook Goolsby
T-PLL | ATLL | CTCL | T-LGL (CD3+) | NK-LGL (CD3- ) | AITL | ALCL | |
---|---|---|---|---|---|---|---|
TdT | - | - | - | - | - | ||
CD1 | - | - | - | - | - | ||
CD2 | ++ | ++ | ++ | ++ | ++ | ++ | |
CD3 | ++ | ++ | ++ | ++ | - | ++ | |
TCRa b | ++ | ++ | ++ | ++ | - | ||
TCRg d | - | - | - | +- | - | ||
CD4+/CD8- | + | ++ | ++ | - | - | + | |
CD4+/CD8+ | +- | - | - | ± | - | + | |
CD4- /CD8+ | +- | - | - | ++ | +- | - | |
CD4- /CD8- | - | - | - | - | ++ | - | |
CD5 | ++ | ++ | ++ | ++ | - | ++ | |
CD7 | ++s | +- | +- | ++ | ++ | ||
CD10 | 50% aberrant | ||||||
CD16 | - | - | - | ± /+ | ++ | ||
CD25 | + | +- | |||||
CD26 | - | - | |||||
CD56 | - | - | - | ± | ++ | ||
CD57 | - | - | - | ++ | + | ||
CD25 | ± w | ++s | +- | +- | NR | ||
HLA-DR | - | +- | +- | + | + |
5.1 Sezary
- CD4+/CD7- en CD4+/CD26- kan als tumormarker gebruikt worden
- zie Novelli et al.